Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.

[1]  A. Bhalla,et al.  Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[3]  S. Kalko,et al.  Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis , 2016, Scientific Reports.

[4]  R. Moreau,et al.  Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. , 2015, Journal of hepatology.

[5]  R. Franchis.  Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension , 2015 .

[6]  Ezio Fornasiere,et al.  Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial , 2015, Hepatology.

[7]  X. Salvatella,et al.  Human serum albumin, systemic inflammation, and cirrhosis. , 2014, Journal of hepatology.

[8]  Emmanuel A Tsochatzis,et al.  Liver cirrhosis , 2014, The Lancet.

[9]  A. Bhalla,et al.  Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study , 2013, The American Journal of Gastroenterology.

[10]  M. Pavesi,et al.  Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. , 2012, Journal of hepatology.

[11]  A. Bhalla,et al.  Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. , 2012, Journal of hepatology.

[12]  P. Ginès,et al.  Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. , 2010, Journal of hepatology.

[13]  S. Møller.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[14]  C. Leevy,et al.  Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.

[15]  E. Christensen,et al.  Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome , 2010, Hepatology.

[16]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[17]  V. Arroyo,et al.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. , 2008, Gastroenterology.

[18]  Detlef Schuppan,et al.  Liver cirrhosis , 2008, The Lancet.

[19]  A. Krag,et al.  Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome , 2007, Hepatology.

[20]  A. Fotopoulos,et al.  Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. , 2007, Journal of hepatology.

[21]  M. Navasa,et al.  Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. , 2006, Gastroenterology.

[22]  V. Boddi,et al.  Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. , 2006, World journal of gastroenterology.

[23]  R. Groszmann,et al.  The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule , 2006, Hepatology.

[24]  O. Garin,et al.  Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  P. Ginès,et al.  Management of complications of cirrhosis in patients awaiting liver transplantation. , 2005, Journal of hepatology.

[26]  Peter Bacchetti,et al.  Serum sodium predicts mortality in patients listed for liver transplantation , 2005, Hepatology.

[27]  R. Fisher,et al.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death , 2004 .

[28]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[29]  Mohamed Rela,et al.  Pretransplant MELD score and post liver transplantation survival in the UK and Ireland , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  M. Morrisey,et al.  MELD score predicts 1‐year patient survival post‐orthotopic liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  W. Kim,et al.  Burden of liver disease in the United States: Summary of a workshop , 2002, Hepatology.

[32]  K Weissenborn,et al.  Neuropsychological characterization of hepatic encephalopathy. , 2001, Journal of hepatology.

[33]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[34]  E. Casiglia,et al.  Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites , 1998, Hepatology.

[35]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[36]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[37]  Vicente Arroyo,et al.  Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis , 1988, Hepatology.

[38]  S. Sherlock,et al.  The effect of repeated albumin infusions in patients with cirrhosis. , 1962, The Lancet.

[39]  A. Gasbarrini,et al.  Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study , 2017 .

[40]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[41]  John E. Ware,et al.  SF-36 Health Survey. , 1990 .

[42]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.